1. Adamus W, Leonard J, Tröger W (1995) Phase I clinical trial with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer’s disease. Life Sci 56: 883–890
2. Aisen P (1997) Inflammation and Alzheimer’s disease: mechanisms and therapeutic strategies. Gerontology 43: 143–149
3. Aisen P, Marin D, Altstiel L, Goodwin C, Baruch B, Jacobson R, Rayn T, Davis K (1996) A pilot study of prednisone in Alzheimer’s disease. Dementia 7: 201–206
4. Augustinsson L, Blennow K, Blomstrandt C, Brane G, Ekman R, Fredman P, Karlsson I, Kihlgren M, Lehmann W, Lekman A, Mansson J, Ramström I, Wallin A, Wikkelsö C, Gottfries C, Svennerholm L (1997) Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients. Dementia 8: 26–33
5. Auteri A, Mosca A, Lattuada N, Luzzana M, Zecca L, Radice D, Imhimbo B (1993) Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. Eur J Clin Pharmacol 45: 373–376